Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
•To evaluate the efficacy of atezolizumab (atezo) as measured by investigator-assessed progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in atezolizumab + carboplatin + pemetrexed versus carboplatin + pemetrexed •To evaluate the efficacy of atezo as measured by overall survival (OS)
Critère d'inclusion
- Non-squamous, Non-small cell lung cancer